



3901 S. Seventh Street  
Terre Haute, Indiana 47802  
(812) 232-0021  
(800) 678-8474  
www.regionalhospital.com

September 1, 2004

Materials Licensing Section,  
U.S. Nuclear Regulatory Commission,  
Region III  
2443 Warrenville Road,  
Lisle, IL 60532

Reference: **License # 13-09649-02**

Gentlemen,

Please accept this letter and attachments in duplicate as our application to amend the above referenced License to authorize Joseph A. Harasimowicz, Jr, M.D. for the use of I-131 iodide for treatment of hyperthyroidism.

Please note that Dr. Harasimowicz is listed on our license as the authorized user of byproduct material for diagnostic purposes. For his training and experience for the use of I-131 iodide, please refer to the attached copy of Byproduct Material License No. 45-19782-01 issued to Southside Community Hospital, Farmville, Virginia 23901.

We hope the above information is satisfactory.

Sincerely,

  
Aynan Ghoniem, M.D.

SEP 10 2004

### MATERIALS LICENSE

uant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter 1, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

**Licensee**

1. Southside Community Hospital
2. 800 Oak Street  
Farmville, Virginia 23901-1199

In accordance with the letter dated  
**February 7, 2000**

3. License No. 45-19782-01

is amended in its entirety to read as follows:

4. Expiration Date: April 30, 2002

5. Docket No. 030-19230

6. Byproduct, source, and/or special nuclear material

- A. Any byproduct material identified in 10 CFR 35.100
- B. Any byproduct material identified in 10 CFR 35.200
- C. Iodine 131

7. Chemical and/or physical form

- A. Any radiopharmaceutical identified in 10 CFR 35.100
- B. Any radiopharmaceutical identified in 10 CFR 35.200
- C. Sodium iodide in capsule form

8. Maximum amount that licensee may possess at any one time under this license

- A. As needed
- B. As needed
- C. 1.11 gigabecquerels (30 millicuries)

9. Authorized Use:

- A. Medical use described in 10 CFR 35.100.
- B. Medical use described in 10 CFR 35.200.
- C. Treatment of hyperthyroidism.

### CONDITIONS

10. Location for use: Southside Community Hospital  
800 Oak Street  
Farmville, Virginia

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.  
45-19782-01

Docket No.  
030-19230

Amendment No.  
15


11. The Radiation Safety Officer (RSO) for this license is Joseph A. Harasimowicz, Jr., M.D., and in his absence, Dorothy F. Cooney, M.D., Alternate RSO.

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users

Material and Use

- |                                      |   |
|--------------------------------------|---|
| A. James S. Strong, M.D.             | For medical uses described in 10 CFR 35.100 and 35.200.   |
| B. Raymond L. Hassett, M.D.          | For medical uses described in 10 CFR 35.100 and 35.200.   |
| C. John O. Stover, M.D.              | For medical uses described in 10 CFR 35.100, 35.200 and iodine 131 as sodium iodide for the treatment of hyperthyroidism. |
| D. George Yama, M.D.                 | For medical uses described in 10 CFR 35.100 and 35.200.   |
| E. John A. Weaver, M.D.              | For medical uses described in 10 CFR 35.100 and 35.200.   |
| F. Joseph A. Harasimowicz, Jr., M.D. | For medical uses described in 10 CFR 35.100, 35.200 and iodine 131 as sodium iodide for the treatment of hyperthyroidism. |



13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35 for establishing decommissioning financial assurance.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**


License No. 45-19782-01
Docket No. 030-19230
Amendment No. 15

14. Except as specifically provided otherwise in the license and as provided in 10 CFR 35.51, the licensee shall conduct its program in accordance with statements, representations, and procedures contained in the documents including any enclosures, listed below. The U. S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated March 6, 1992

B. Letters dated:

- 1) February 10, 1992
- 2) March 15, 1993 [Name new RSO, authorized user]
- 3) April 27, 1993 [Add authorized user]
- 4) October 21, 1996 [RSC and RSO approval to add Dr. Price as an AU via ministerial change]
- 5) February 3, 1997 [Change of RSO; Addition of I-131 and Use of Xe-133 gas]
- 6) February 25, 1997 [Addition of Associate RSO]
- 7) May 15, 1997 [Facsimile transmitting licensee's OMB for I-131 use]
- 8) May 15, 1997 [Facsimile regarding additional information on the use of I-131 and Xe-133]
- 9) July 7, 1997 [Remove D. Cooney; add Dr. McKenzie as associate RSO and user]
- 10) July 20, 1998 [Change RSO (D. Cooney); Remove 2 Authorized Users (E. McKenzie, N. O'Donohue); Add 2 AUs (T. Dunn, E. Hassett)]
- 11) September 3, 1998 [Facsimile with letter dated 9/2/98 regarding additional information for New RSO and 2 Authorized Users]
- 12) September 30, 1998 [Correction of Amendment No. 13 to change alternate RSO]
- 13) March 23, 1999 [Request to change RSO (J. Harasimowicz) and Alt. RSO (D. Cooney); Delete 2 AUs (T. Dunn, M. Wakat); and Add 4 AUs (J. Stover, G. Yama, J. Weaver, J. Harasimowicz)]
- 14) April 29, 1999 [Additional information regarding 3 AUs training and experience]
- 15) May 12, 1999 [Facsimile regarding clarification of material use for 2 AUs]
- 16) February 7, 2000 [Request to change location of NM dept. at hospital; and Change in use/frequency of dosimetry]
- 17) February 27, 2000 [Request to change patient release criteria for therapy patients]



FOR THE U. S. NUCLEAR REGULATORY COMMISSION

WADE T. LOO

DATE **MAR 15 2000**

BY Wade T. Loo

Region II, Division of Nuclear Materials Safety  
61 Forsyth Street, S.W., Suite 23T85  
Atlanta, Georgia 30303

**Terre Haute  
Regional Hospital**

3901 South 7th Street  
Terre Haute, Indiana 47802

RETURN SERVICE  
REQUESTED

FIRST CLASS



MATERIALS LICENSING SECTION  
U.S. NUCLEAR REGULATORY COMMISSION  
REGION III  
2443 Warrentonville Road  
LISLE, IL 60532

60532+3673 21

